- Home
- ALHC vs IBRX Comparison
ALHC vs IBRX Comparison
Compare ALHC & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALHC
- IBRX
- Stock Information
- Founded
- ALHC 2013
- IBRX 2014
- Country
- ALHC United States
- IBRX United States
- Employees
- ALHC N/A
- IBRX N/A
- Industry
- ALHC Medical Specialities
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALHC Health Care
- IBRX Health Care
- Exchange
- ALHC Nasdaq
- IBRX Nasdaq
- Market Cap
- ALHC 2.3B
- IBRX 1.9B
- IPO Year
- ALHC 2021
- IBRX N/A
- Fundamental
- Price
- ALHC $14.58
- IBRX $2.94
- Analyst Decision
- ALHC Buy
- IBRX Strong Buy
- Analyst Count
- ALHC 8
- IBRX 3
- Target Price
- ALHC $12.43
- IBRX $13.58
- AVG Volume (30 Days)
- ALHC 1.7M
- IBRX 6.3M
- Earning Date
- ALHC 02-25-2025
- IBRX 11-12-2024
- Dividend Yield
- ALHC N/A
- IBRX N/A
- EPS Growth
- ALHC N/A
- IBRX N/A
- EPS
- ALHC N/A
- IBRX N/A
- Revenue
- ALHC $2,467,707,000.00
- IBRX $7,332,000.00
- Revenue This Year
- ALHC N/A
- IBRX $2,515.60
- Revenue Next Year
- ALHC $29.24
- IBRX $766.19
- P/E Ratio
- ALHC N/A
- IBRX N/A
- Revenue Growth
- ALHC 43.47
- IBRX 1218.71
- 52 Week Low
- ALHC $4.46
- IBRX $2.28
- 52 Week High
- ALHC $14.79
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- ALHC 76.94
- IBRX 48.30
- Support Level
- ALHC $11.30
- IBRX $2.28
- Resistance Level
- ALHC $12.04
- IBRX $2.54
- Average True Range (ATR)
- ALHC 0.66
- IBRX 0.25
- MACD
- ALHC 0.40
- IBRX 0.10
- Stochastic Oscillator
- ALHC 95.06
- IBRX 64.71
About ALHC Alignment Healthcare Inc.
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.